StockDriftsStockDriftsTop 6 Remedium Capital Partners, LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| ORKA | Oruka Therapeutics Inc | 32.99% | 1.57M | $149.0M | +0.00%(+0) | $24.90(+351.84%) | 2026-06-30 | |
| SYRE | Spyre Therapeutics Inc | 28.78% | 1.46M | $130.0M | +0.55%(+7.94K) | $24.99(+314.69%) | 2026-06-30 | |
| APGE | Apogee Therapeutics Inc | 17.24% | 586.7K | $77.9M | +0.53%(+3.10K) | $57.86(+132.55%) | 2026-06-30 | |
| DMRA | Damora Therapeutics Inc | 11.78% | 2.05M | $53.2M | +0.00%(+0) | $23.80(+29.11%) | 2026-06-30 | |
| JBIO | Jade Biosciences Inc | 7.76% | 1.58M | $35.1M | +0.00%(+0) | $12.03(+105.40%) | 2026-06-30 | |
| CBIO | Crescent Biopharma Inc | 1.44% | 361.3K | $6.5M | new | $11.88(+47.75%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (2 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +117.13% |
| Top 20 Holdings Unweighted | — | — | — | — | +93.02% |
Remedium Capital Partners, LLC reports $451.63M in US-listed equity holdings across 6 positions in its most recent 13F filing. Its largest disclosed positions are ORKA (33.0%), SYRE (28.8%) and APGE (17.2%). The top 20 holdings account for 99.99% of reported assets. Its disclosed equity book has returned +117.13% cumulatively over 2 quarters. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Remedium Capital Partners, LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Remedium Capital Partners, LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2104501). View Remedium Capital Partners, LLC’s 13F filings on SEC